Overview
NephTox in numbers
The atlas at a glance — how anti-cancer nephrotoxicity distributes across injury signatures, severity, reversibility, drug families, and eras.
251+
Agents catalogued
251
Deep profiles
868
Verified citations
14
Injury signatures
27%
of cancer patients develop AKI within 5 years
Christiansen et al., Eur J Intern Med 2011 ↗
53%
carry hidden kidney impairment at diagnosis
Launay-Vacher et al., Cancer 2007 ↗
4.7×
higher odds of death with in-hospital AKI
Salahudeen et al., CJASN 2013 ↗
~1 in 3
cisplatin courses cause acute kidney injury
Tang et al., Nat Rev Nephrol 2022 ↗
Injury signatures by agent count
Prerenal / Hemodynamic AKI144
Electrolyte Wasting136
Acute Tubular Necrosis67
Glomerular Injury / Proteinuria40
Hypertension29
Thrombotic Microangiopathy27
Pseudo-AKI26
Acute Interstitial Nephritis24
Crystal / Obstructive Nephropathy17
SIADH / Hyponatremia16
Fanconi Syndrome7
Chronic Interstitial Nephropathy6
Hemorrhagic Cystitis3
Renal Cysts1
Severity
Severe11
Moderate114
Mild126
Reversibility
Often irreversible6
Partially reversible32
Variable33
Reversible180
Top drug families
Kinase inhibitors (TKIs)67
Other targeted agents50
Alkylating agents22
Antimetabolites17
Bispecifics / T-cell engagers14
Antibody-drug conjugates13
Checkpoint inhibitors13
Anti-angiogenic (VEGF)11
Monoclonal antibodies (other)9
Hormonal / endocrine8
Agents by era of approval
1940s1
1950s1
1960s2
1970s3
1980s8
1990s10
2000s4
2010s24
2020s51
Distributions are computed across the 251 deeply-profiled agents (severity, reversibility, injuries) and the 251+ catalog (families, eras). A drug counts once per injury it causes.